#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Esther Wollert, Sandra Spalek, and Charles Tapley Hoyt"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY AS PATTERN "^\d+$"
DEFINE NAMESPACE PUBCHEM AS PATTERN "^\d+$"

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE MESH     AS URL "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh-names.belns"
DEFINE NAMESPACE CHEBI    AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE   AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
DEFINE NAMESPACE NCBIGENE AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE GFAM     AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE HGNC     AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE MIRBASE  AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE HBP      AS URL "https://raw.githubusercontent.com/pharmacome/terminology/785431732a26d6809b4162d98b95687d16404e63/export/hbp.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel
# --------------------------------------------------------------------
DEFINE NAMESPACE CTO      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE MGI      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns"
DEFINE NAMESPACE RGD      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns"
DEFINE NAMESPACE INTERPRO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns"

###############
# Annotations #
###############

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "30116051"}

#autophagy refers to macroautophagy

SET Evidence = "The heterotrimeric serine/threonine kinase 5ʹ‑AMP‑
activated protein kinase (AMPK) and mammalian target
of rapamycin complex 1 (mTORC1) trigger autophagy
and repress mitophagy 3,10,20–23   (BOX 2; FIG. 3) ."
p(FPLX:AMPK) -> bp(GO:macroautophagy)
p(FPLX:mTORC1) -> bp(GO:macroautophagy)
p(FPLX:AMPK) -| bp(GO:mitophagy)
p(FPLX:mTORC1) -| bp(GO:mitophagy)

SET Evidence = "Unc-51-like
kinase 1 (ULK1) is primarily an autophagy-initiating
protein 3,10,19 , as is the mTORC1- suppressed transcrip-
tion factor EB (TFEB), which orchestrates the synthesis
of lysosomal and other proteins critical for maintaining
ALN flux 20–23 ."
p(HGNC:ULK1) -> bp(GO:macroautophagy)
p(HGNC:TFEB) -> bp(GO:macroautophagy)

SET Evidence = "Because the class III deacetylase NAD-
dependent protein deacetylase sirtuin 1 (SIRT1) requires
nicotinamide adenine dinucleotide (NAD) to sustain its
activity, this positive regulator of autophagy may also be
considered a sensor 24 ."
a(CHEBI:"NAD(+)") -> act(p(HGNC:SIRT1))
p(HGNC:SIRT1) -> bp(GO:macroautophagy)

SET Evidence = "AMPK is central to several mechanisms that trigger
autophagy — most importantly, activating phosphoryla-
tion of ULK1 (Ser317 and Ser777) and inhibitory phos-
phorylation of mTORC1  (REFS21,31) ."
p(FPLX:AMPK) -> p(HGNC:ULK1, pmod(Ph,S,317))
p(FPLX:AMPK) -> p(HGNC:ULK1, pmod(Ph,S,777))
p(HGNC:ULK1, pmod(Ph,S,317)) -> act(p(HGNC:ULK1))
p(HGNC:ULK1, pmod(Ph,S,777)) -> act(p(HGNC:ULK1))
p(FPLX:AMPK) -> p(FPLX:mTORC1, pmod(Ph))
p(FPLX:mTORC1, pmod(Ph)) -| act(p(FPLX:mTORC1))

SET Evidence = "Conversely, mTORC1
inhibits ULK1 by Ser757 phosphorylation 3,4,31 ."
p(FPLX:mTORC1) -> p(HGNC:ULK1, pmod(Ph,S,757))
p(HGNC:ULK1, pmod(Ph,S,757)) -| act(p(HGNC:ULK1))

SET Evidence = "mTORC1
also restrains autophagy by preventing nuclear translo-
cation of TFEB 20 ."
p(FPLX:mTORC1) -| tloc(p(HGNC:TFEB), MESH:Cytoplasm, MESH:"Cell Nucleus")
tloc(p(HGNC:TFEB), MESH:Cytoplasm, MESH:"Cell Nucleus") -> bp(GO:macroautophagy)

SET Evidence = "Other transcription factors that posi-
tively regulate autophagy include forkhead box protein
O1 (FOXO1) and FOXO3  (REF.22) . "
p(HGNC:FOXO1) -> bp(GO:macroautophagy)
p(HGNC:FOXO3) -> bp(GO:macroautophagy)

SET Evidence = "Conversely, repression
is effected by signal transducer and activator of transcrip-
tion 3 (STAT3) and possibly zinc-finger protein with
KRAB and SCAN domains 3 (ZKSCAN3), although its
role has been disputed 22,32 ."
p(HGNC:STAT3) -| bp(GO:macroautophagy)
p(HGNC:ZKSCAN3) -| bp(GO:macroautophagy)

SET Evidence = " SIRT1 is activated by AMPK-
mediated increases in nicotinamide, and it drives the ALN
by inhibiting mTORC1, inducing FOXO1 and FOXO3
and activating key regulatory proteins such as ATG5,
ATG7 and LC3."
p(FPLX:AMPK) -> a(CHEBI:"NAD(+)")
a(CHEBI:"NAD(+)") -> act(p(HGNC:SIRT1))
act(p(HGNC:SIRT1)) -| act(p(FPLX:mTORC1))
act(p(HGNC:SIRT1)) -> act(p(HGNC:FOXO1))
act(p(HGNC:SIRT1)) -> act(p(HGNC:FOXO3))
act(p(HGNC:SIRT1)) -> act(p(HGNC:ATG5))
act(p(HGNC:SIRT1)) -> act(p(HGNC:ATG7))
#LC3 is MAP1LC3A
act(p(HGNC:SIRT1)) -> act(p(HGNC:MAP1LC3A))

SET Evidence = "Activation of ULK1 triggers
autophagosome nucleation through activating phospho-
rylation of AMBRA and beclin 1 within the autophagy-
specific PIK3C3 complex 10   (FIG. 3) ."
act(p(HGNC:ULK1)) -> bp(GO:"autophagosome assembly")
act(p(HGNC:ULK1)) -> p(HGNC:AMBRA1, pmod(Ph))
p(HGNC:AMBRA1, pmod(Ph)) -> act(p(HGNC:AMBRA1))
act(p(HGNC:AMBRA1)) -> bp(GO:"autophagosome assembly")
act(p(HGNC:ULK1)) -> p(HGNC:BECN1, pmod(Ph))
p(HGNC:BECN1, pmod(Ph)) -> act(p(HGNC:BECN1))
act(p(HGNC:BECN1)) -> bp(GO:"autophagosome assembly")

SET Evidence = "Tau, α-synuclein and TDP43 are substrates for
CMA degradation, as are amyloid precursor protein (APP)
but not amyloid-β fragment 42 (Aβ42) itself 3,45–47,48 . "
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:MAPT))
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:SNCA))
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:TARDBP))
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:APP))
bp(GO:"chaperone-mediated autophagy") causesNoChange deg(a(CHEBI:"amyloid-beta polypeptide 42"))

SET Evidence = "Htt is not efficiently cleared by CMA, and the same
appears to hold for its fragments and mutant and post-
translationally modified forms, although the precise
role of CMA in Htt elimination remains to be more fully
defined 2,45–47 ."
bp(GO:"chaperone-mediated autophagy") causesNoChange deg(p(HGNC:HTT))

SET Evidence = "Interestingly, the UPS is important for elimination of tau
and other neurotoxic proteins in post synaptic dendritic
compartments (a key site of spreading), where it plays
a more general role favouring synaptic plasticity, den-
dritogenesis and memory formation 49,52 ."
SET MeSHAnatomy = "Dendrites"
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") -> deg(p(HGNC:MAPT))
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") -> bp(GO:"regulation of synaptic plasticity")
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") -> bp(GO:"dendrite development")
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") -> bp(GO:memory)
UNSET MeSHAnatomy

SET MeSHDisease = "Alzheimer Disease"

SET Evidence = "Second, while
decr1eases in beclin 1 levels in AD remain to be confirmed,
SIRT1 expression is diminished 24 . "
path(MESH:"Alzheimer Disease") -| p(HGNC:SIRT1)

SET Evidence = "Third, apolipoprotein E
allele 4 (APOE4), a major risk allele for sporadic AD,
is associated with increased generation and accumula-
tion of Aβ42  (REFS59,60) ."
a(HBP:HBP00030) -> path(MESH:"Alzheimer Disease")
a(HBP:HBP00030) -> a(CHEBI:"amyloid-beta polypeptide 42")

SET Evidence = "In addition to decreased degradation, one
consequence is leakage of asparaginyl endopeptidase
into the cytosol, where it generates toxic fragments of
tau 61 . "
SET MeSHAnatomy = "Cytosol"
a(HBP:HBP00030) -> p(HGNC:LGMN)
p(HGNC:LGMN) -> p(HGNC:MAPT, frag("?"))
UNSET MeSHAnatomy

SET Evidence = "Fourth, genetic mutations and anomalies of presenilin 1,
a dominant negative gene linked to AD, are associated
with reduced lysosomal v-ATPase-mediated acidifica-
tion 40,63 , a compromised ALN and deficient mitophagy 64 . "
g(HGNC:PSEN1, var("?")) positiveCorrelation path(MESH:"Alzheimer Disease")
g(HGNC:PSEN1, var("?")) negativeCorrelation act(complex(GO:"lysosomal proton-transporting V-type ATPase complex"))
g(HGNC:PSEN1, var("?")) negativeCorrelation bp(GO:autophagy)
g(HGNC:PSEN1, var("?")) negativeCorrelation bp(GO:mitophagy)

SET Evidence = "Fifth, mutations in
APP similarly disrupt endosomal and lysosomal func-
tion, in part owing to accumulation of the β-secretase-
generated, carboxy-terminal and Aβ42-containing
fragment of APP called C99  (REF.66) ."
g(HGNC:APP, var("?")) -| act(a(GO:endosome))
g(HGNC:APP, var("?")) -| act(a(GO:lysosome))
g(HGNC:APP, var("?")) -> a(HBP:HBP00081)

SET Evidence = "Sixth, Aβ42 compro-
mises the function of AMPK to impede initiation of the
ALN 67 . "
a(CHEBI:"amyloid-beta polypeptide 42") -| act(p(FPLX:AMPK))
a(CHEBI:"amyloid-beta polypeptide 42") -| bp(GO:"autophagosome assembly")

SET Evidence = " Seventh, Aβ42 obstructs the UPS and CMA 47,68 . "
a(CHEBI:"amyloid-beta polypeptide 42") -| bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")
a(CHEBI:"amyloid-beta polypeptide 42") -| bp(GO:"chaperone-mediated autophagy")

SET Evidence = "Both aggregates and mutant forms of tau likewise
block the proteasome, and its ability to degrade hyper-
phosphorylated and oligomeric tau is reduced compared
with its ability to degrade physiological tau 3,55,68 . "
a(HBP:HBP00006) -| act(complex(GO:"proteasome complex"))
p(HGNC:MAPT, var("?")) -| act(complex(GO:"proteasome complex"))
complex(GO:"proteasome complex") -> deg(p(HGNC:MAPT))
p(HGNC:MAPT, pmod(HBP:HBP00007)) -| deg(p(HGNC:MAPT))

SET Evidence = "Finally,
while physiological tau possesses KFERQ motifs and is
degraded by CMA, aggregates, mutant forms and frag-
ments interfere with CMA 45,47 ."
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:MAPT))
a(HBP:HBP00006) -| bp(GO:"chaperone-mediated autophagy")
p(HGNC:MAPT, var("?")) -| bp(GO:"chaperone-mediated autophagy")
p(HGNC:MAPT, frag("?")) -| bp(GO:"chaperone-mediated autophagy")

SET MeSHDisease = "Parkinson Disease"

SET Evidence = "First, autosomal
recessive forms of early-onset PD are associated with
mutations in PTEN-induced putative kinase protein 1
(PINK1) and the E3 ubiquitin-protein ligase parkin; these
mutations lead to deficits in the mitophagic removal of
damaged mitochondria 69,70   (BOX 2) ."
p(HGNC:PINK1, var("?")) -- path(MESH:"Parkinson Disease")
p(HGNC:PRKN, var("?")) -- path(MESH:"Parkinson Disease")
p(HGNC:PINK1, var("?")) -| bp(GO:mitophagy)
p(HGNC:PRKN, var("?")) -| bp(GO:mitophagy)

SET Evidence = "Second, the GTPase
leucine-rich repeat serine/threonine-protein kinase 2
(LRRK2) is the most commonly mutated protein in
late-onset, familial PD. "
p(HGNC:LRRK2, var("?")) -- path(MESH:"Parkinson Disease")

SET Evidence = " Some of these lead to an
impairment of the ALN owing to reduced activation of
beclin 1; another repercussion may be altered process-
ing of APP, providing an unexpected link to AD 69,71–73 . "
p(HGNC:LRRK2, var("?")) -| bp(GO:autophagy)
p(HGNC:LRRK2, var("?")) -| act(p(HGNC:BECN1))
p(HGNC:LRRK2, var("?")) -- bp(HBP:HBP00073)

SET Evidence = "Third, α-synuclein mutations, triplications or excesses
amplify the ALN burden, interfere with auto phagosome
formation and irreversibly disrupt the lysosomal mem-
brane 1,3,44,56 ."
p(HGNC:SNCA, var("?")) -| bp(GO:"autophagosome assembly")
p(HGNC:SNCA, var("?")) -| a(GO:"lysosomal membrane")

SET Evidence = "Fourth, homozygous mutations of lyso-
somal β-glucocerebrosidase (βGCase; also known as
GBA) provoke the LSD Gaucher disease, which is linked
to decreased ALN flux, α-synuclein accumulation and a
fivefold increase in risk of PD 43  (Supplementary Box 1)."
p(HGNC:GBA, var("?")) -> path(MESH:"Gaucher Disease")
p(HGNC:GBA, var("?")) -| bp(GO:autophagy)
p(HGNC:GBA, var("?")) -> a(HBP:HBP00016)
p(HGNC:GBA, var("?")) -> path(MESH:"Parkinson Disease")

SET Evidence = "Sixth,
aggregates and mutant forms of α-synuclein disrupt the
proteasome in dopaminergic neurons. "
SET MeSHAnatomy = "Dopaminergic Neurons"
a(HBP:HBP00016) -| complex(GO:"proteasome complex")

SET Evidence = "Furthermore,
mutations in the gene encoding parkin and several other
genes are linked to reduced UPS activity 2,56,69,79,80 ."
p(HGNC:PRKN, var("?")) -| bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")

SET Evidence = " In addition, CMA is disrupted by sev-
eral genetic mutations occurring in PD, including muta-
tions in LRRK2  (REFS2,3,45–47,55,69,80) . "
p(HGNC:LRRK2, var("?")) -|  bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")

SET Evidence = " CMA dysfunction in
PD favours the accumulation of α- synuclein and leads to
inactivation of the dopaminergic neuron survival factor,
myocyte-specific enhancer factor 2D (MEF2D) 2,45,47,55 ."
bp(GO:"chaperone-mediated autophagy") -> deg(p(HGNC:SNCA))
bp(GO:"chaperone-mediated autophagy") -> act(p(HGNC:MEF2D))

SET MeSHDisease = "Frontotemporal Dementia"

SET Evidence = "However, in light of common risk genes
such as SQSTM1 (which encodes p62) and chromosome 9
open reading frame 72 (C9ORF72), FTD is increasingly
linked to ALS 82,83 . "
p(HGNC:SQSTM1) -- path(MESH:"Frontotemporal Dementia")
p(HGNC:C9orf72) -- path(MESH:"Frontotemporal Dementia")

SET MeSHDisease = "Amyotrophic Lateral Sclerosis"

SET Evidence = "ALS shares many causal
genes with FTD, including SQSTM1, CHMP2B, TBK1
(which encodes tank-binding kinase 1), OPTN (which
encodes optineurin) and other genes associated with
deficits in ALN and mitophagy."
p(HGNC:SQSTM1) -- path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:CHMP2B) -- path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:TBK1) -- path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:OPTN) -- path(MESH:"Amyotrophic Lateral Sclerosis")

SET Evidence = "For example, mutations
in OPTN and TBK1 interfere with cargo loading 82,84,87 ."
p(HGNC:OPTN, var("?")) -| bp(GO:"cargo loading into vesicle")
p(HGNC:TBK1, var("?")) -| bp(GO:"cargo loading into vesicle")

SET Evidence = "Mutations in C9ORF72 (the most prevalent risk gene for
familial ALS and FTD) are likewise linked to disruption
of the ALN, including interference with dynactin–dynein
coordinated transport of autophagosomes along axons
of motor neurons to the perikarya 82,88 ."
p(HGNC:C9orf72, var("?")) -| bp(GO:autophagy)

SET MeSHDisease = "Huntington Disease"

SET Evidence = "Mutant Htt is cleared by autophagy, but it
compromises the ALN because of decreased cargo load-
ing and impaired autophagosome formation and trans-
port 55,56,68,92 . "
bp(GO:autophagy) -> deg(p(HGNC:HTT, var("?")))
p(HGNC:HTT, var("?")) -| bp(GO:autophagy)
p(HGNC:HTT, var("?")) -| bp(GO:"cargo loading into vesicle")
p(HGNC:HTT, var("?")) -| bp(GO:"autophagosome assembly")

UNSET MeSHDisease

SET Evidence = "For example, methylene blue coun-
ters tau oligomerization and promotes autophagy 101,102
(Supplementary Table 4)."
a(CHEBI:"methylene blue") -| a(HBP:HBP00009)
a(CHEBI:"methylene blue") -> bp(GO:autophagy)

SET Evidence = " Indeed, clonidine and rilmenidine, two
G i  /G o -coupled α 2 -adrenergic receptor and imidazoline 1
receptor agonists, stimulate autophagy and cleared Htt
in cellular 103  and animal models of HD 104 ."
SET MeSHDisease = "Huntington Disease"
a(CHEBI:clonidine) -> bp(GO:autophagy)
a(CHEBI:clonidine) -> deg(p(HGNC:HTT))
a(CHEBI:Rilmenidine) -> bp(GO:autophagy)
a(CHEBI:Rilmenidine) -> deg(p(HGNC:HTT))

SET Evidence = " Genetic knockdown of calpain 1 or
calpain 2 or overexpression of their endogenous inhibitor,
calpastatin, increased autophagy and cleared aggregates
in SK-N-SH cells overexpressing a mutant form of Htt 103 ."
p(HGNC:CAPN1) -| bp(GO:autophagy)
p(HGNC:CAPN1) -| deg(p(HGNC:HTT, var("?")))
p(HGNC:CAPN2) -| bp(GO:autophagy)
p(HGNC:CAPN2) -| deg(p(HGNC:HTT, var("?")))
p(HGNC:CAST) -| act(p(HGNC:CAPN1))
p(HGNC:CAST) -| act(p(HGNC:CAPN2))
p(HGNC:CAST) -> bp(GO:autophagy)
p(HGNC:CAST) -> deg(p(HGNC:HTT, var("?")))

SET Evidence = " Calpeptin, a cell-permeable
calpain inhibitor, can also reduce Htt proteinopathy via
induction of autophagy 103,105 ."
a(CHEBI:Calpeptin) -| act(p(HGNC:CAPN1))
a(CHEBI:Calpeptin) -| act(p(HGNC:CAPN2))
a(CHEBI:Calpeptin) -> bp(GO:autophagy)
a(CHEBI:Calpeptin) -> deg(p(HGNC:HTT, var("?")))

UNSET MeSHDisease

SET Evidence = " Calpain inhibition by cal-
pastatin or pharmacological agents also confers neuropro-
tective effects in other NDA models, including improved
clearance of tau, α-synuclein and SOD1  (REFS54,106,107) ."
p(HGNC:CAST) -> deg(p(HGNC:MAPT))
p(HGNC:CAST) -> deg(p(HGNC:SNCA))
p(HGNC:CAST) -> deg(p(HGNC:SOD1))

SET Evidence = "The aminoimidazole derivative 5-aminoimidazole-
4-carboxamide ribonucleotide (AICAR) undergoes intra-
cellular transformation to an AMP analogue that triggers
AMPK-mediated autophagy 21,108 ."
a(CHEBI:"AICA ribonucleotide") -> act(p(FPLX:AMPK))
act(p(FPLX:AMPK)) -> bp(GO:autophagy)

SET Evidence = " Another direct facilitator of AMPK, A769662,
elicited autophagy and reduced the burden of Htt in a
striatal cell line derived from knock-in mice expressing
a humanized form of mutant Htt (exon 1 containing
seven polyglutamine repeats) 111 ."
a(PUBCHEM:54708532) -> act(p(FPLX:AMPK))
a(PUBCHEM:54708532) -> deg(p(HGNC:HTT, var("?")))

SET Evidence = " Selenium deficits have
been linked to AD, and thus it is interesting that seleno-
methionine boosted ALN flux, from AMPK recruit-
ment through autophagosome formation to lysosomal
degradation, in the 3×Tg AD mouse model 112 ."
a(CHEBI:"selenium(2+)") negativeCorrelation path(MESH:"Alzheimer Disease")
a(CHEBI:selenomethionine) -> bp(GO:autophagy)
a(CHEBI:selenomethionine) -> act(p(FPLX:AMPK))
a(CHEBI:selenomethionine) -> bp(GO:"autophagosome assembly")
a(CHEBI:selenomethionine) -> bp(GO:"lysosomal microautophagy")

SET Evidence = "The ‘anti-ageing’ agent resveratrol is thought to indi-
rectly recruit AMPK via activation of calcium/calmodulin-
dependent protein kinase kinase 2 (CAMKK2), which,
acting in synergy with Ca 2+ , exerts its effects via Thr172
phosphorylation 113 . This action, among others (below),
is involved in its reduction of Aβ levels in N2a cells and
neurons 114  and the elimination of Aβ and Htt in animal
models of AD and HD 114,115 ."
a(CHEBI:resveratrol) -> act(p(HGNC:CAMKK2))
composite(p(HGNC:CAMKK2),a(CHEBI:"calcium(2+)")) -> p(FPLX:AMPK, pmod(Ph,T,172))
a(CHEBI:resveratrol) -| a(CHEBI:"amyloid-beta")
a(CHEBI:resveratrol) -| p(HGNC:HTT)

SET Evidence = "The antidiabetic drug metformin, a prototypical
activator of AMPK, induced autophagy and increased
longevity in mice 116 . "
a(CHEBI:metformin) -> act(p(FPLX:AMPK))
a(CHEBI:metformin) -> bp(GO:autophagy)

SET Evidence = " Moreover, reductions in levels of
hyper phosphorylated tau and Aβ were seen in metformin-
treated neurons 117,118 , while it blunted neuronal loss in a
neurochemical lesion model of PD in mice 119 ."
a(CHEBI:metformin) -| a(CHEBI:"amyloid-beta")
a(CHEBI:metformin) -| p(HGNC:MAPT, pmod(HBP:HBP00007))
SET MeSHDisease = "Parkinson Disease"
a(CHEBI:metformin) -| bp(GO:"neuron death")
UNSET MeSHDisease

SET Evidence = "The di-glucose derivative trehalose inhibits the sol-
ute carrier 2A (SLC2A) family of glucose transporters
to promote AMPK-induced autophagy and reduce
neurotoxic protein load, although it also exerts other
actions downstream in the ALN 4,120 . "
a(CHEBI:"alpha,alpha-trehalose") -| act(p(HGNC:SLC2A9))
a(CHEBI:"alpha,alpha-trehalose") -> act(p(FPLX:AMPK))
act(p(FPLX:AMPK)) -> bp(GO:autophagy)

SET Evidence = " It also proved effective in cellu-
lar models of PD, HD and AD 121,122 , as well as in mouse
models of HD, AD and tauopathies, where it cleared
aggregates, reduced neurodegeneration and ameliorated
motor and cognitive performance 123–125 ."
a(CHEBI:"alpha,alpha-trehalose") -| bp(HP:Neurodegeneration)
a(CHEBI:"alpha,alpha-trehalose") -| a(HBP:HBP00006)
a(CHEBI:"alpha,alpha-trehalose") -| a(HBP:HBP00016)
a(CHEBI:"alpha,alpha-trehalose") -| a(HBP:HBP00017)
a(CHEBI:"alpha,alpha-trehalose") -| a(HBP:HBP00018)
a(CHEBI:"alpha,alpha-trehalose") -> bp(GO:"motor behavior")
a(CHEBI:"alpha,alpha-trehalose") -> bp(GO:cognition)

SET Evidence = "Lithium ions inhibit inositol monophosphatase to
deplete inositol triphosphate."
a(CHEBI:"lithium(1+)") -| act(p(HGNC:IMPA1))
a(CHEBI:"lithium(1+)") -| a(PUBCHEM:55310)

SET Evidence = " This mechanism may be
involved in its promotion of autophagy, reduction in cel-
lular levels of α-synuclein, SOD1, Htt and tau 126 , ame-
lioration of motor function in a P301L mouse model of
tauopathy 127  and slowing of disease progression in SOD1
mice 128 . "
a(CHEBI:"lithium(1+)") -> bp(GO:autophagy)
a(CHEBI:"lithium(1+)") -| p(HGNC:SNCA)
a(CHEBI:"lithium(1+)") -| p(HGNC:SOD1)
a(CHEBI:"lithium(1+)") -| p(HGNC:HTT)
a(CHEBI:"lithium(1+)") -| p(HGNC:MAPT)
a(CHEBI:"lithium(1+)") -> bp(GO:"motor behavior")

SET Evidence = "Other compounds that act through AMPK acti-
vation  include  the  antiaggregant  methylene  blue
(Supplementary Box 1), which elevated levels of beclin  1,
p62 and LC3, induced autophagy and suppressed tau in
organotypic neuronal cultures and a mouse model of
FTD 101,102 ."
a(CHEBI:"methylene blue") -> act(p(FPLX:AMPK))
a(CHEBI:"methylene blue") -> bp(GO:autophagy)
a(CHEBI:"methylene blue") -> p(HGNC:BECN1)
a(CHEBI:"methylene blue") -> p(HGNC:MAP1LC3A)
a(CHEBI:"methylene blue") -> p(HGNC:DCTN4)
a(CHEBI:"methylene blue") -| act(p(HGNC:MAPT))

SET Evidence = " In addition, calcitriol (the active metabolite
of vitamin D 3 ) elicited AMPK-dependent autophagy in
a neurochemical lesion-induced model of PD 129."
SET MeSHDisease = "Parkinson Disease"
a(CHEBI:calcitriol) -> act(p(FPLX:AMPK))
a(CHEBI:calcitriol) -> bp(GO:autophagy)
UNSET MeSHDisease

SET Evidence = "One major strategy for promoting autophagy
is the relief of its repression by mTORC1."
p(FPLX:mTORC1) -| bp(GO:macroautophagy)

SET Evidence = "This kinase
is classically inactivated by rapamycin, which binds to
the modulatory protein 12 kDa FK506-binding protein
(FKBP12; also known as FKBP1A)."
complex(p(HGNC:FKBP1A),a(CHEBI:sirolimus)) -| act(p(FPLX:mTORC1))

SET Evidence = "Enhancing auto-
phagy with rapamycin reduced levels of α-synuclein, FUS
and Htt 130–132 . "
a(CHEBI:sirolimus) -> bp(GO:autophagy)
a(CHEBI:sirolimus) -| p(HGNC:SNCA)
a(CHEBI:sirolimus) -| p(HGNC:FUS)
a(CHEBI:sirolimus) -| p(HGNC:HTT)

SET Evidence = "Likewise, temsirolimus reduced the accumulation
of phosphorylated tau in SH-SY5Y cells and P301S
tauopathy mice 137 ."
a(CHEBI:Temsirolimus) -| a(HBP:HBP00006)

SET Evidence = " It also removed cellular aggregates
of mutant Htt and improved motor performance in a
mouse model of HD, reduced α-synuclein aggregation
and afforded neuroprotection in a lesion-based model of
PD and depleted mutant ataxin 3 in a mouse model
of supraspinal cerebellar ataxia type 3  (REFS133,138,139) . "
SET MeSHDisease = "Huntington Disease"
a(CHEBI:Temsirolimus) -| a(HBP:HBP00017)
a(CHEBI:Temsirolimus) -> bp(GO:"motor behavior")
SET MeSHDisease = "Parkinson Disease"
a(CHEBI:Temsirolimus) -| a(HBP:HBP00016)
a(CHEBI:Temsirolimus) -| bp(HP:Neurodegeneration)
SET MeSHDisease = "Machado-Joseph Disease"
a(CHEBI:Temsirolimus) -| p(HGNC:ATXN3, var("?"))

SET Evidence = "The natural product curcumin induced macro-
autophagy and protected rotenone-treated dopaminer-
gic neurons 141  in addition to accelerating the elimination
of mutant α-synuclein-A53T by repressing mTORC1 in a
cellular model of early-onset PD, although it also exerts
other actions such as inhibition of p300-mediated pro-
tein acetylation and of aggregation 142,143 . "
a(CHEBI:curcumin) -> bp(GO:macroautophagy)
a(CHEBI:curcumin) -| act(p(FPLX:mTORC1))
a(CHEBI:curcumin) -> deg(p(HGNC:SNCA, sub(A,53,T)))

SET Evidence = "Pro-autophagic
effects of curcumin are reflected in improved function
in cellular and animal models of PD and AD, as well as
reduced levels of α-synuclein aggregates 144  or Aβ and tau
oligomers 145,146 ."
a(CHEBI:curcumin) -| a(HBP:HBP00016)
a(CHEBI:curcumin) -| a(HBP:HBP00022)
a(CHEBI:curcumin) -| a(HBP:HBP00009)

SET Evidence = "Indeed, TFEB over-
expression reduced amyloid plaques in a APP/PS1 mouse
model 148 . "
p(HGNC:TFEB) -| a(HBP:HBP00018)

SET Evidence = " Moreover, the flavonol fisetin stimulated auto-
phagic degradation of phosphorylated tau in cortical neu-
rons via mTORC1-dependent activation of TFEB and the
cytoprotective transcription factor nuclear factor eryth-
roid 2-related factor 2 (NFE2L2) 149 . Fisetin also reduced
Aβ accumulation in an APP/PS1 mouse model of AD 150 . "
a(CHEBI:fisetin) -> bp(GO:macroautophagy)
bp(GO:macroautophagy) -> deg(p(HGNC:MAPT, pmod(HBP:HBP00007)))
a(CHEBI:fisetin) -> act(p(FPLX:mTORC1))
act(p(FPLX:mTORC1)) -> act(p(HGNC:TFEB))
act(p(FPLX:mTORC1)) -> act(p(HGNC:NFE2L2))
a(CHEBI:fisetin) -| a(HBP:HBP00018)

SET Evidence = "Tyrosine-protein kinase ABL1 is a proto- oncogene
that  negatively  regulates autophagy,  partly  acting
upstream of the RAC serine/threonine-protein kinase
(AKT)–mTORC1 axis."
p(HGNC:ABL1) -| bp(GO:macroautophagy)

SET Evidence = " ABL1 is overactivated in AD and
tauopathies such as FTD 152 ."
path(MESH:"Alzheimer Disease") -> act(p(HGNC:ABL1))
path(MESH:"Frontotemporal Dementia") -> act(p(HGNC:ABL1))

SET Evidence = "Inactivation of ABL1 with
brain-penetrant nilotinib conferred neuroprotective
autophagy in mouse models of PD 153 ."
a(CHEBI:nilotinib) -| act(p(HGNC:ABL1))
a(CHEBI:nilotinib) -> bp(GO:macroautophagy)
a(CHEBI:nilotinib) -| bp(HP:Neurodegeneration)

SET Evidence = " Activity of the deacetylase SIRT1 declines with
age, partially owing to limited availability of its co fac-
tor, nicotinamide 24,56,156 . "
bp(GO:aging) -| act(p(HGNC:SIRT1))
bp(GO:aging) -| a(CHEBI:"NAD(+)")

SET Evidence = "Resveratrol can stimulate SIRT1 via AMPK (see
above), and it also possesses an AMPK-independent
mode of SIRT1 recruitment that participates in blunting
the neurotoxicity of Aβ25–35 fragments in PC12 cells 160 . "
a(CHEBI:resveratrol) -> act(p(FPLX:AMPK))
act(p(FPLX:AMPK)) -> act(p(HGNC:SIRT1))
a(CHEBI:resveratrol) -| act(p(HGNC:APP, frag(23_35)))

SET Evidence = "Cilostazol (a phosphodiesterase 3 inhibitor) clears
Aβ42 from neuronal cell lines by promoting autophagy,
upregulating beclin 1, ATG5 and LC3, downregulating
mTORC1 and inducing lysosomal cathepsin B; these
actions of cilostazol involve activation of SIRT1 as well
as upstream Tyr172 phosphorylation of AMPK 108,162,163 ."
a(CHEBI:cilostazol) -| a(CHEBI:"amyloid-beta polypeptide 42")
a(CHEBI:cilostazol) -> bp(GO:macroautophagy)
a(CHEBI:cilostazol) -> p(HGNC:BECN1)
a(CHEBI:cilostazol) -> p(HGNC:ATG5)
a(CHEBI:cilostazol) -> p(HGNC:MAP1LC3A)
a(CHEBI:cilostazol) -| p(FPLX:mTORC1)
SET MeSHAnatomy = "Lysosomes"
a(CHEBI:cilostazol) -> p(HGNC:CTSB)
UNSET MeSHAnatomy
a(CHEBI:cilostazol) -> act(p(HGNC:SIRT1))
a(CHEBI:cilostazol) -> p(FPLX:AMPK, pmod(Ph,Y,172))

SET Evidence = "Cilostazol improved cognition and reduced levels of
Aβ42 and hyperphosphorylated tau following intra-
cerebroventricular injection of Aβ25–35 into mice 162,163 ."
a(CHEBI:cilostazol) -> bp(GO:cognition)
a(CHEBI:cilostazol) -| a(CHEBI:"amyloid-beta polypeptide 42")
a(CHEBI:cilostazol) -| p(HGNC:MAPT, pmod(HBP:HBP00007))

SET Evidence = "Spermidine inhibits
the acetylation of ATG7 and histone H3, while induc-
ing beclin 1 via blockade of its cleavage by caspase 3
(REF.168) . "
a(CHEBI:spermidine) -| p(HGNC:ATG7, pmod(Ac))
a(CHEBI:spermidine) -| p(FPLX:"Histone_H3", pmod(Ac))
a(CHEBI:spermidine) -> act(p(HGNC:BECN1))
a(CHEBI:spermidine) -| act(p(HGNC:CASP3))
act(p(HGNC:CASP3)) -> p(HGNC:BECN1, frag("?"))
p(HGNC:BECN1, frag("?")) -| act(p(HGNC:BECN1))

SET Evidence = "In
addition, the plant-derived alkaloid isorhynchophylline
upregulated beclin 1 independently of mTORC1 and
promoted autophagic clearance of α-synuclein, although
its precise mechanism of action remains to be clarified 175 . "
a(CHEBI:Isorhynchophylline) -> p(HGNC:BECN1)
a(CHEBI:Isorhynchophylline) -| a(HBP:HBP00016)

SET Evidence = "Disruption of this Bcl-2–beclin 1 complex
is an alternative approach for promoting autophagy,
as achieved in mouse fibroblasts by the BH3 mimetic
ABT-737  (REF.177) ."
complex(p(HGNC:BCL2),p(HGNC:BECN1)) -| bp(GO:macroautophagy)

SET Evidence = "The multi-modal agent resveratrol induced the expression of ATG4 and promoted autophagosome formation."
a(CHEBI:resveratrol) -> r(FPLX:ATG4)
a(CHEBI:resveratrol) -> bp(GO:"autophagosome assembly")

SET Evidence = " An unusual approach to augmenting
autophagosome formation is represented by the brain-
penetrant autophagy enhancer 99 (AUTEN-99), which
blocks myotubularin-related protein 14 (MTMR14, also
known as Jumpy), a phosphatase that inhibits the phos-
phoinositide 3-kinase (PI3K)-mediated generation of
the autophagosome membrane  (FIG. 3) . AUTEN-99 aug-
mented autophagic flux in isolated neurons, increased
markers of autophagy in mouse brain and slowed neuro-
degeneration in D. melanogaster models of PD and HD 181 ."
a(PUBCHEM:16240819) -| act(p(HGNC:MTMR14))
p(HGNC:MTMR14) -| act(p(FPLX:PI3K))
act(p(FPLX:PI3K)) -> a(GO:"autophagosome membrane")
a(PUBCHEM:16240819) -> bp(GO:macroautophagy)
a(PUBCHEM:16240819) -| bp(HP:Neurodegeneration)

SET Evidence = "The microtubule stabilizers
paclitaxel and epothilone A countered Aβ42-induced
cytoskeletal disruption — and moderated excessive UPR
— in neurons 182 ."
a(CHEBI:"amyloid-beta polypeptide 42") -| a(GO:microtubule)
a(CHEBI:paclitaxel) -> a(GO:microtubule)
a(CHEBI:"epothilone A") -> a(GO:microtubule)

SET Evidence = "Furthermore, epothilone D countered
microtubule disruption and cognitive deficits in aged
P301S/P19 AD mice 183 . "
a(CHEBI:"epothilone D") -> a(GO:microtubule)
a(CHEBI:"epothilone D") -> bp(GO:cognition)

SET Evidence = "Interestingly, genetic or pharmacological activation of
RAB5 countered neurodegeneration in mouse C9ORF72
models of ALS and FTD 187 ."
SET MeSHDisease = {"Frontotemporal Dementia","Amyotrophic Lateral Sclerosis"}
act(p(HGNC:RAB5A)) -| bp(HP:Neurodegeneration)
UNSET MeSHDisease

SET Evidence = "Second, the TFEB inducer 2-hydroxypropyl-β-cyclo-
dextrin promoted the acidity of lysosomes in neurons 190 ."
a(PUBCHEM:129688311) -> bp(GO:"lysosomal lumen acidification")

SET Evidence = "Third, acidic nanoparticles such as polylactic acid and
poly(lactide- co-glycolide) increase acidification  (BOX 3) ."
a(CHEBI:"poly(lactic acid) polymer") -> bp(GO:"lysosomal lumen acidification")
a(CHEBI:"poly(D,L-lactic acid-co-glycolic acid)") -> bp(GO:"lysosomal lumen acidification")

SET Evidence = "Fourth, activation of the lysosomal Ca 2+  channel mucol-
ipin transient receptor potential channel 1 (TRPML1)
with a synthetic agonist (ML-SA1) increased lysoso-
mal Ca 2+  release, lowered pH and promoted Aβ clear-
ance 191,192 . "
a(PUBCHEM:2880983) -> act(p(HGNC:MCOLN1))
act(p(HGNC:MCOLN1)) -> tloc(a(CHEBI:"calcium(2+)"),MESH:Lysosomes,MESH:Cytoplasm)
act(p(HGNC:MCOLN1)) -> bp(GO:"lysosomal lumen acidification")
act(p(HGNC:MCOLN1)) -| a(CHEBI:"amyloid-beta")

SET Evidence = " Indeed, clioquinol countered disruption
of autophagy by chloroquine in retinal cells, reduced
Aβ42 accumulation in CHO cells expressing APP and
mutant presenilin 1 and diminished amyloid misfolding
and aggregation in Tg2576 AD mice 196,197 ."
a(CHEBI:chlorohydroquinone) -| bp(GO:macroautophagy)
a(CHEBI:"5-chloro-7-iodoquinolin-8-ol") -> bp(GO:macroautophagy)
a(CHEBI:"5-chloro-7-iodoquinolin-8-ol") -| a(CHEBI:"amyloid-beta polypeptide 42")

SET Evidence = " It increased expression of βGCase, normalized
autophagy and accelerated degradation of α-synuclein
in a stem cell model of dopaminergic neurons derived
from patients with PD bearing mutations in βGCase 200 . "
#It: Ambroxol
SET MeSHDisease = "Parkinson Disease"
a(CHEBI:ambroxol) -> p(HGNC:GBA)
a(CHEBI:ambroxol) -> bp(GO:macroautophagy)
a(CHEBI:ambroxol) -> deg(p(HGNC:SNCA))
UNSET MeSHDisease

SET Evidence = "Ambroxol, which also decreased ER stress in D. mela-
nogaster 201 , reduced α-synuclein levels in overexpress-
ing, transgenic mice 202 ."
a(CHEBI:ambroxol) -| bp(GO:"response to endoplasmic reticulum stress")
a(CHEBI:ambroxol) -| p(HGNC:SNCA)

SET Evidence = "Harnessing TFEB by 2-hydroxypropyl-β-cyclodextrin
promoted clearance of proteolipid aggregates and α-syn-
uclein in a cellular model of PD 195,204 .It also augmented
the elimination of Aβ in a Tg19959/CRND8 mouse
model of AD 173 ."
SET MeSHDisease = "Parkinson Disease"
a(PUBCHEM:129688311) -| a(HBP:HBP00016)
SET MeSHDisease = "Alzheimer Disease"
a(PUBCHEM:129688311) -| a(CHEBI:"amyloid-beta")
UNSET MeSHDisease

SET Evidence = " The protein kinase C (PKC) activator
HEP14 stimulated nuclear translocation of TFEB to
boost lysosomal gene transcription and reduced Aβ
plaques in APP/PS1 AD mouse brains 151 ."

SET Evidence = "One promising agent is the hydroxylamine deriva-
tive arimoclomol, which increases the activity of HSP70
by augmenting transcriptional activity of HSF1  (REF.210) ."
a(PUBCHEM:9568077) -> tscript(p(HGNC:HSF1))
tscript(p(HGNC:HSF1)) -> act(p(FPLX:HSPA))

SET Evidence = "Among compounds that inhibit HSP90,
geldanamycin promoted elimination of both hyper-
phosphorylated tau and oligomeric α-synuclein in cell
lines 219,220 . "
a(CHEBI:geldanamycin) -| act(p(FPLX:HSP90))
a(CHEBI:geldanamycin) -| p(HGNC:MAPT, pmod(HBP:HBP00007))
a(CHEBI:geldanamycin) -| a(HBP:HBP00016)

SET Evidence = "The less cytotoxic
analogue of geldanamycin, 17-AAG, has improved
brain penetrance. It decreased Aβ levels 223 , improved
memory 224  and lowered tau in transgenic AD mice 224 .
17-AAG also reduced α-synuclein oligomers in H4
cells 220 .  "
#17-AAG is tanespimycin
a(CHEBI:tanespimycin) -| act(p(FPLX:HSP90))
SET MeSHDisease = "Alzheimer Disease"
a(CHEBI:tanespimycin) -| a(CHEBI:"amyloid-beta")
a(CHEBI:tanespimycin) -> bp(GO:memory)
a(CHEBI:tanespimycin) -| p(HGNC:MAPT)
UNSET MeSHDisease
a(CHEBI:tanespimycin) -| a(HBP:HBP00016)

SET Evidence = "Another HSP90 inhibitor, HSP990, has shown
promise in lowering Htt aggregates and improving
motor performance in two mouse models of HD 225 ."
a(PUBCHEM:46216556) -| act(p(FPLX:HSP90))
a(PUBCHEM:46216556) -| a(HBP:HBP00017)

SET Evidence = " Chronic administration of CGS-21680, a selective
agonist of the AC-coupled adenosine A 2A  receptor, restored
proteasomal activity in cellular and murine models for HD
via PKA-mediated Ser120 phosphorylation of the RPT6
component of the 19S subunit 231 ."
a(PUBCHEM:3086599) -> act(complex(GO:"proteasome complex"))
a(PUBCHEM:3086599) -> kin(p(FPLX:PKA))
#rpt6 subunit encoded by PSMC5 gene
kin(p(FPLX:PKA)) -> p(HGNC:PSMC5, pmod(Ph,S,120))

SET Evidence = "Another kinase that activates the proteasome (RPT6
subunit) — and directs it to dendritic spines — is
CAMKK2  (REF.227) ."
p(HGNC:CAMKK2) -> act(p(HGNC:PSMC5))

SET Evidence = "Third, cellular inhibitor of apoptosis 1 (CIAP1;
also known as BIRC2) specifically binds mutant SOD1
and drives it to proteasomal degradation."
complex(p(HGNC:BIRC2),p(HGNC:SOD1)) -> deg(p(HGNC:SOD1))

SET Evidence = "Finally, mirroring its inhibitory
influence on the ALN, mTORC1 suppresses the UPS by
impeding the formation and assembly of proteasomal
subunits. "
p(FPLX:mTORC1) -| bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")
p(FPLX:mTORC1) -| bp(GO:"proteasome assembly")

SET Evidence = "Nonetheless, overexpression of LAMP2A accelerated
CMA-related clearance of α-synuclein and afforded pro-
tection of dopaminergic neurons 45 , and several routes
to potential pharmacological exploitation exist. "
p(HGNC:LAMP2) -> bp(GO:"chaperone-mediated autophagy")
p(HGNC:LAMP2) -> deg(p(HGNC:SNCA))

SET Evidence = "The UPS and CMA are
disrupted by neurotoxic proteins like Aβ42 and tau,
hence, their early and preventive reinforcement prior to
Aβ42 and tau accumulation may be critical."
a(CHEBI:"amyloid-beta polypeptide 42") -| bp(GO:"chaperone-mediated autophagy")
a(CHEBI:"amyloid-beta polypeptide 42") -| bp(GO:"chaperone-mediated autophagy")
p(HGNC:MAPT) -| bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")
p(HGNC:MAPT) -| bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")

SET Evidence = "Supporting the relevance of sestrin 2,
it has been shown to protect dopaminergic neurons
from the neurotoxin rotenone via AMPK-transduced
autophagy 247 ."
p(HGNC:SESN2) -> act(p(FPLX:AMPK))
p(HGNC:SESN2) -> bp(GO:macroautophagy)

SET Evidence = " Sestrin 2 over expression also prompted
mTORC1-dependent autophagy in cortical neurons in a
presenilin-knockout model of AD."
SET MeSHDisease = "Alzheimer Disease"
p(HGNC:SESN2) -> bp(GO:macroautophagy)
UNSET MeSHDisease

SET Evidence = "Aβ42 and amylin (a pancreas-derived, AD-associated
protein found in brain) are substrates for degradation by
IDE, which also irreversibly traps Aβ42 and α-synuclein,
preventing their aggregation and promoting ALN and
UPS elimination 259 ."
p(HGNC:IDE) -> deg(a(CHEBI:"amyloid-beta"))
p(HGNC:IDE) -> deg(p(HGNC:IAPP))
p(HGNC:IDE) -| a(HBP:HBP00016)
p(HGNC:IDE) -| a(HBP:HBP00018)

SET Evidence = "Cerebral levels of IDE are reduced in
early AD and in mouse models of AD, whereas, mirroring
AD amyloidosis, Aβ42 accumulates in mice genetically
depleted of IDE. "
SET MeSHAnatomy = "Cerebrum"
path(MESH:"Alzheimer Disease") -| p(HGNC:IDE)
UNSET MeSHAnatomy

SET Evidence = " In a vicious circle, Aβ42 itself decreases
IDE expression, although it may prompt its release from
glia 254,259 ."
a(CHEBI:"amyloid-beta polypeptide 42") -| p(HGNC:IDE)

SET Evidence = " IDE also degrades and prevents the forma-
tion of α-synuclein fibrils 259 ."
p(HGNC:IDE) -| a(HBP:HBP00092)

SET Evidence = "Similar to IDE, neprilysin
catabolizes Aβ42, and its loss in mouse models of AD
and in patients with AD alike also contributes to Aβ42
accumulation 253,256,260 ."
p(HGNC:MME) -> deg(a(CHEBI:"amyloid-beta polypeptide 42"))
path(MESH:"Alzheimer Disease") -| p(HGNC:MME)

SET Evidence = "Like IDE
and neprilysin, plasmin degrades Aβ42 and blocks
Aβ42-induced toxicity, suggesting that the decrease
in its levels in AD is involved in the evolution of
AD 254,256,261 . "
p(HGNC:PLG) -> deg(a(CHEBI:"amyloid-beta polypeptide 42"))

SET Evidence = " Plasmin also degrades α-synuclein to retard
intercellular spreading 262 ."
p(HGNC:PLG) -> deg(p(HGNC:SNCA))

SET Evidence = " Finally, the extracellular and intracellular
serine protease neurosin (also known as KLK6) cleaves
α- synuclein. "
p(HGNC:KLK6) -> deg(p(HGNC:SNCA))

SET Evidence = "In
regard to pharmacological manipulation, substances
such as epigallocatechin and somatostatin promote the
expression, secretion and (allosterically) catalytic activ-
ity of IDE and neprilysin in parallel with an increase
in the degradation of Aβ peptides 259,280 ."
a(CHEBI:"(-)-epigallocatechin") -> p(HGNC:IDE)
a(CHEBI:"(-)-epigallocatechin") -> sec(p(HGNC:IDE))
a(CHEBI:"(-)-epigallocatechin") -> act(p(HGNC:IDE))
a(CHEBI:"(-)-epigallocatechin") -> p(HGNC:MME)
a(CHEBI:"(-)-epigallocatechin") -> sec(p(HGNC:MME))
a(CHEBI:"(-)-epigallocatechin") -> act(p(HGNC:MME))
a(CHEBI:somatostatin) -> p(HGNC:IDE)
a(CHEBI:somatostatin) -> sec(p(HGNC:IDE))
a(CHEBI:somatostatin) -> act(p(HGNC:IDE))
a(CHEBI:somatostatin) -> p(HGNC:MME)
a(CHEBI:somatostatin) -> sec(p(HGNC:MME))
a(CHEBI:somatostatin) -> act(p(HGNC:MME))

SET Evidence = " Furthermore,
expression of progranulin in the hippocampus of AD
mice reduces the density of amyloid plaques by enhanc-
ing the activity of neprilysin 281 ."
p(HGNC:GRN) -> act(p(HGNC:MME))
p(HGNC:GRN) -| a(HBP:HBP00018)

SET Evidence = "The antibiotic
rifampicin likewise promoted Aβ42 clearance by induc-
ing BBB-localized LRP1 and P glycoprotein 1  (REFS273,292) . "
a(CHEBI:rifampicin) -> deg(a(CHEBI:"amyloid-beta polypeptide 42"))
SET MeSHAnatomy = "Blood-Brain Barrier"
a(CHEBI:rifampicin) -> act(p(HGNC:LRP1))
a(CHEBI:rifampicin) -> act(p(FPLX:"GPIb_IX_V"))
UNSET MeSHAnatomy

SET Evidence = "Interestingly, resver-
atrol downregulated RAGE as well as MMP9 — an effect
that is related to decreased hippocampal load of Aβ42
(REF.297) . "
a(CHEBI:resveratrol) -| p(HGNC:AGER)
a(CHEBI:resveratrol) -| p(HGNC:MMP9)
SET MeSHAnatomy = "Hippocampus"
a(CHEBI:resveratrol) -| a(CHEBI:"amyloid-beta polypeptide 42")
UNSET MeSHAnatomy

SET Evidence = "Activation of aquaporin 4 channels on perivascular
astrocytes to aid the glymphatic elimination of cerebral
Aβ and other toxic proteins is a potential strategy for
stimulating clearance."
act(p(HGNC:AQP4)) -> deg(a(CHEBI:"amyloid-beta"))
